An absolutely irresistible brunch invitation: 2/18/23. Click for more!

FDA approves fast-acting Viagra rival, Stendra

By Sex and Love editor on Mon, Apr 30, 2012 at 10:50 am

Clinical trials of Stendra showed that it started working in as little as 15 minutes, compared to an hour for Viagra.

While Stendra also works by increasing blood flow to the penis, the clinical trials suggest that Stendra is more selective. This specificity is expected to result in fewer side-effects.

With over 30 million men in the US suffering from some form of ED, it is anticipated that Stendra will pull in about $300 million in sales annually. In contrast, Viagra earned about $2 billion in 2011. Interestingly enough, a new erection medication may not be enough to arouse investors. Market analysts are more excited about the earning potential of Vivus's obesity drug, Qnexa, which will be reviewed by the FDA in July.

Read more at FoxNews.com

Follow Alfie on Twitter or Facebook and email him if interested in writing about Sex & Love

[
      {
        "name": "Ad - NativeInline - Injected",
        "component": "12461396",
        "insertPoint": "3",
        "requiredCountToDisplay": "5"
      },{
        "name": "Real 1 Player (r2) - Inline",
        "component": "12436357",
        "insertPoint": "2/3",
        "requiredCountToDisplay": "9"
      }
    ]

Avanafil, which will sell under the name, Stendra, just became the first new erectile dysfunction (ED) drug to be approved by the FDA in a decade.

Stendra's parent company, Vivus Inc., will compete with the three other ED medications on the US market: Viagra, Cialis, and Levitra. However, the new drug may have a leg up on the competition.